Business Wire

TEMENOS

29.4.2020 08:32:10 CEST | Business Wire | Press release

Share
Temenos Launches New SaaS Propositions to Help Banks Respond to Covid-19 While Accelerating Their Digital Transformation

Temenos (SIX: TEMN), the banking software company, today announced the launch of eight propositions – using innovative Explainable AI (XAI) and cloud technologies – to help banks in their immediate response to the Covid-19 crisis. Temenos is supporting banks to ensure business continuity, enhance digital engagement to meet clients’ changing needs, and manage socioeconomic pressures. These Covid-19 propositions are immediately available worldwide. Delivered as Temenos SaaS, they are deployed quickly, easily and can be implemented remotely, if required.

Temenos is bringing together its dynamic community at Temenos Community Forum Online on 29-30 April to explore ‘Solutions for the New Normal’. Over 5,000 attendees have registered for the action-packed, virtual summit, with 43 product announcements, 49 live Q&A sessions with Temenos experts and over 30 demos showing Temenos’ latest innovations from cloud to digital engagement technologies and Explainable AI. At TCF Online Temenos will showcase how its solutions are addressing the fast-growing needs for digitalization, personalization and greater agility, solving the immediate Covid-19 challenges and creating sustainable business models for the future.

Max Chuard, Chief Executive Officer, Temenos, said: “I am proud of the AI and cloud-advanced propositions we have delivered to help banks address their most pressing needs during Covid-19. I am also proud of our family of Temenos employees, who have worked tirelessly to make this response a reality. As the leader in banking software, we are relentlessly investing in R&D to keep banks running as they assist SMEs, corporate and retail customers at a time of financial distress. In the ‘New Normal’, the need for modern digital banking will be greater than ever. Only Temenos can provide banks the richest banking functionality and the most advanced cloud-native technology to help them deliver value to their customers and build sustainable growth in the future.”

To support banks, Temenos launched the following AI-driven SaaS technology propositions which are immediately available to help banks with the Covid-19 crisis:

  • Enhancing customer digital interactions – With the surge in digital banking volumes Temenos is helping banks meet customers’ needs for intimate digital interactions, particularly those who typically bank in branches. Temenos Infinity Engage gives customers a personal digital communications channel to connect with their trusted advisors within the bank.
  • Helping banks give financial relief to SMEs and retail customers with Explainable AI (XAI) – Temenos’ new XAI models delivered as SaaS help banks assist small businesses and retail customers with fast loan approval and viable financial products. These XAI models delivered as SaaS will help banks digitally on-board, conduct eligibility checks, process loan applications and establish the right product pricing. These models include Temenos AI - Urgent Relief Loan, Temenos AI-Personalization and Temenos AI – SME Smart Decisioning.
  • US Paycheck Protection Program quick roll out – Temenos is helping US banks and credit unions with Temenos Infinity, the digital omnichannel product, to rapidly process loan applications from small businesses under the US government’s PPP and give them the funding they need. Temenos working together as one team with Atlantic Union Bank helped the bank build a brand new digital loan portal specifically for PPP in less than a week.
  • Rapidly adapt AML, KYC and fraud management to new emerging threats – Temenos has partnered with Microsoft to offer fast access to its AI-driven, Temenos Financial Crime Mitigation SaaS solution to help banks combat the rise in cybercrime due to Covid-19. Temenos has proven its ability to support banks of all sizes without disruption, providing comprehensive AML/KYC/fraud management while all bank employees are working remotely.
  • Helping banks rapidly launch or adapt products to respond to Covid-19 – Governments and regulators are asking banks to make product changes, such as payments holidays and loan restructurings. Temenos Continuous Deployment delivered as Temenos SaaS supports banks to accelerate changes in test and live environments, providing remote, automated, secure DevOps tools. This means that all necessary product changes can take place in these fast changing, and resource constrained times.
  • Providing training opportunities for bank employees – Temenos opened its online learning platform with over 400 courses for all Temenos products and sandboxes for free to allow bank users to experience and test Temenos’ latest technology innovations from their own home. More than 3,000 banking practitioners have registered to increase their knowledge on Temenos products and upskill team members. To request free access by visit here .

– Ends –

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye